PARP14 promotes the proliferation and gemcitabine chemoresistance of pancreatic cancer cells through activation of NF‐κB pathway
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Carcinogenesis"
DOI: 10.1002/mc.23011
Abstract: Pancreatic cancer (PC) is the most fatal gastrointestinal malignancy in the world, with a 5‐year relative survival of only 8%. Poly(ADP‐ribose) polymerase (PARP)14, a member of the macro‐PARP subfamily proteins, has been reported to participate… read more here.
Keywords: gem resistance; proliferation gemcitabine; pancreatic cancer; parp14 ... See more keywords
Lauric Acid Overcomes Hypoxia-Induced Gemcitabine Chemoresistance in Pancreatic Ductal Adenocarcinoma
Sign Up to like & getrecommendations! Published in 2023 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms24087506
Abstract: Although gemcitabine (GEM) is widely used in chemotherapy for pancreatic ductal adenocarcinoma (PDA), drug resistance restricts its clinical effectiveness. To examine the mechanism of GEM resistance, we established two GEM-resistant cell lines from human PDA… read more here.
Keywords: cell; gem; gem resistance; ductal adenocarcinoma ... See more keywords
Role and molecular mechanisms of hypoxia-derived exosomal miR-301a on gemcitabine resistance in pancreatic cancer
Sign Up to like & getrecommendations! Published in 2025 at "Oncology Letters"
DOI: 10.3892/ol.2025.15352
Abstract: Pancreatic cancer is a highly aggressive digestive malignancy and gemcitabine (GEM)-based chemotherapy remains a cornerstone of its treatment despite widespread resistance. The present study employed human pancreatic cancer cell lines to construct a hypoxia model,… read more here.
Keywords: pancreatic cancer; gem resistance; mir 301a;